{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:37:57Z","timestamp":1789324677659,"version":"build-2803163510"},"reference-count":163,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.drudis.2022.05.016","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T11:44:28Z","timestamp":1653133468000},"page":"1895-1912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents"],"prefix":"10.1016","volume":"27","author":[{"given":"Jinhe","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Jea","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meehyein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.05.016_b0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.05.016_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.05.016_b0015","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3:96ra77","author":"Sirota","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2022.05.016_b0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.drudis.2022.05.016_b0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2022.05.016_b0030","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/337476a0","article-title":"Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins","volume":"337","author":"Fischer","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.05.016_b0035","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature11087","article-title":"Apolipoprotein E controls cerebrovascular integrity via cyclophilin A","volume":"485","author":"Bell","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.05.016_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2014.02.010","article-title":"Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir","volume":"184","author":"Carbajo-Lozoya","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.drudis.2022.05.016_b0045","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1158\/1541-7786.MCR-19-1144","article-title":"Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer","volume":"18","author":"Davra","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drudis.2022.05.016_b0050","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1128\/jvi.71.9.7110-7113.1997","article-title":"Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions","volume":"71","author":"Dorfman","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0055","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0092-8674(00)81823-1","article-title":"Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid","volume":"87","author":"Gamble","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2022.05.016_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/29dffb2a-5d37-4196-b166-b0b15bc2f3fd","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"Kaul","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2022.05.016_b0065","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1462-5822.2009.01286.x","article-title":"Cyclophilin A interacts with influenza A virus M1 protein and impairs the early stage of the viral replication","volume":"11","author":"Liu","year":"2009","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.drudis.2022.05.016_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2022.05.016_b0075","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/pro.5560061103","article-title":"Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein","volume":"6","author":"Vajdos","year":"1997","journal-title":"Protein Sci"},{"key":"10.1016\/j.drudis.2022.05.016_b0080","first-page":"1508","article-title":"Cyclosporine nephrotoxicity and dermal vascular alterations in renal transplants","volume":"21","author":"Shen","year":"1989","journal-title":"Transplant Proc"},{"key":"10.1016\/j.drudis.2022.05.016_b0085","first-page":"1554","article-title":"The effect of donor age and sex on cyclosporine associated nephrotoxicity","volume":"21","author":"Iguro","year":"1989","journal-title":"Transplant Proc"},{"key":"10.1016\/j.drudis.2022.05.016_b0090","first-page":"2236","article-title":"Overcoming early cyclosporine nephrotoxicity after liver transplantation","volume":"21","author":"Burdick","year":"1989","journal-title":"Transplant Proc"},{"key":"10.1016\/j.drudis.2022.05.016_b0095","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.05.016_b0100","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2014.06.035","article-title":"Innate and adaptive immune responses in HCV infections","volume":"61","author":"Heim","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2022.05.016_b0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.chom.2014.10.008","article-title":"Hepatitis C virus RNA replication and assembly: living on the fat of the land","volume":"16","author":"Paul","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2022.05.016_b0110","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1128\/JVI.02614-07","article-title":"Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro","volume":"82","author":"Yang","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0115","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2022.05.016_b0120","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1074\/jbc.M109.007625","article-title":"The isomerase active site of cyclophilin A is critical for hepatitis C virus replication","volume":"284","author":"Chatterji","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0125","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/hep.23281","article-title":"Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A","volume":"50","author":"Ciesek","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2022.05.016_b0130","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52237","article-title":"Hepatitis C virus exploits cyclophilin A to evade PKR","volume":"9","author":"Colpitts","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2022.05.016_b0135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","article-title":"HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors","volume":"53","author":"Chatterji","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2022.05.016_b0140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","article-title":"Completion of the entire hepatitis C virus life cycle in genetically humanized mice","volume":"501","author":"Dorner","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.05.016_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005428","article-title":"The Hepatitis C Virus-Induced Membranous Web and Associated Nuclear Transport Machinery Limit Access of Pattern Recognition Receptors to Viral Replication Sites","volume":"12","author":"Neufeldt","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2022.05.016_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003056","article-title":"Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication","volume":"8","author":"Romero-Brey","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2022.05.016_b0155","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.04958-14","article-title":"Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories","volume":"59","author":"Chatterji","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.05.016_b0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/viro.1997.8493","article-title":"Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein","volume":"230","author":"Gale","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2022.05.016_b0165","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1073\/pnas.062055699","article-title":"Regulation of PKR and IRF-1 during hepatitis C virus RNA replication","volume":"99","author":"Pflugheber","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.05.016_b0170","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00532-20","article-title":"ISGylation of Hepatitis C Virus NS5A Protein Promotes Viral RNA Replication via Recruitment of Cyclophilin A","volume":"94","author":"Abe","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0175","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1021\/bi00131a002","article-title":"Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity","volume":"31","author":"Liu","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2022.05.016_b0180","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1073\/pnas.89.9.3686","article-title":"Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A","volume":"89","author":"Fruman","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.05.016_b0185","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.22131","article-title":"The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus","volume":"47","author":"Flisiak","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2022.05.016_b0190","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1128\/AAC.00693-12","article-title":"The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes","volume":"56","author":"Hopkins","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.05.016_b0195","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1093\/hmg\/ddu254","article-title":"NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models","volume":"23","author":"Zulian","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2022.05.016_b0200","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1476-5381.2009.00316.x","article-title":"The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-\/- myopathic mice","volume":"157","author":"Tiepolo","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2022.05.016_b0205","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.1087139","article-title":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China","volume":"302","author":"Guan","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.05.016_b0210","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01826-2019","article-title":"Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via interferon-\u03bb in vitro and in mice","volume":"56","author":"Sauerhering","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2022.05.016_b0215","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coviro.2015.08.004","article-title":"Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication","volume":"14","author":"von Brunn","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108959","article-title":"Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2","volume":"35","author":"Dittmar","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2022.05.016_b0225","doi-asserted-by":"crossref","first-page":"e00876","DOI":"10.1128\/AAC.00876-20","article-title":"Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)","volume":"64","author":"Softic","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.05.016_b0230","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2009.08.029","article-title":"EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation","volume":"209","author":"Seizer","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2022.05.016_b0235","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-020-00426-x","article-title":"CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2022.05.016_b0240","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41392-021-00760-8","article-title":"CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma","volume":"6","author":"Geng","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2022.05.016_b0245","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2215\/CJN.09440620","article-title":"Expression of CD147 and Cyclophilin A in Kidneys of Patients with COVID-19","volume":"16","author":"Su","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.drudis.2022.05.016_b0250","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.celrep.2016.03.074","article-title":"Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication","volume":"15","author":"Lahaye","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2022.05.016_b0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/1348-0421.12387","article-title":"Small ruminant lentiviral Vif proteins commonly utilize cyclophilin A, an evolutionarily and structurally conserved protein, to degrade ovine and caprine APOBEC3 proteins","volume":"60","author":"Yoshikawa","year":"2016","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.drudis.2022.05.016_b0260","doi-asserted-by":"crossref","first-page":"14849","DOI":"10.1073\/pnas.0505659102","article-title":"Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells","volume":"102","author":"Berthoux","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.05.016_b0265","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/JVI.79.1.176-183.2005","article-title":"Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells","volume":"79","author":"Hatziioannou","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0270","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.chom.2014.10.010","article-title":"Macrophage infection via selective capture of HIV-1-infected CD4+ T cells","volume":"16","author":"Baxter","year":"2014","journal-title":"Cell Host Microbe"},{"issue":"536\u201348","key":"10.1016\/j.drudis.2022.05.016_b0275","article-title":"Single HIV-1 Imaging Reveals Progression of Infection through CA-Dependent Steps of Docking at the Nuclear Pore, Uncoating, and Nuclear Transport","volume":"23","author":"Francis","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2022.05.016_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108201","article-title":"Nuclear Import of the HIV-1 Core Precedes Reverse Transcription and Uncoating","volume":"32","author":"Selyutina","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2022.05.016_b0285","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41594-020-0467-8","article-title":"Intrinsic curvature of the HIV-1 CA hexamer underlies capsid topology and interaction with cyclophilin A","volume":"27","author":"Ni","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2022.05.016_b0290","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1006\/jmbi.1997.1051","article-title":"Molecular recognition in the HIV-1 capsid\/cyclophilin A complex","volume":"269","author":"Yoo","year":"1997","journal-title":"J Mol Biol"},{"key":"10.1016\/j.drudis.2022.05.016_b0295","doi-asserted-by":"crossref","first-page":"10203","DOI":"10.1073\/pnas.1404220111","article-title":"Cyclophilin A catalyzes proline isomerization by an electrostatic handle mechanism","volume":"111","author":"Camilloni","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.05.016_b0300","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1128\/jvi.70.7.4299-4310.1996","article-title":"Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization","volume":"70","author":"Colgan","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0305","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/jvi.70.6.3551-3560.1996","article-title":"Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription","volume":"70","author":"Braaten","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0310","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1128\/jvi.70.7.4220-4227.1996","article-title":"Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses","volume":"70","author":"Braaten","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0315","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm910","article-title":"Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors","volume":"9","author":"Towers","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2022.05.016_b0320","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-4690-6-21","article-title":"Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type","volume":"6","author":"Matsuoka","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.drudis.2022.05.016_b0325","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.177.1.443","article-title":"Novel activities of cyclophilin A and cyclosporin A during HIV-1 infection of primary lymphocytes and macrophages","volume":"177","author":"Saini","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2022.05.016_b0330","doi-asserted-by":"crossref","first-page":"12800","DOI":"10.1128\/JVI.78.23.12800-12808.2004","article-title":"Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity","volume":"78","author":"Sokolskaja","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0335","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35738","article-title":"Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2","volume":"7","author":"Kane","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2022.05.016_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.02.100","article-title":"Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5\u03b1 Binding to the Viral Core","volume":"30","author":"Selyutina","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.drudis.2022.05.016_b0345","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03142-20","article-title":"Cytoplasmic CPSF6 Regulates HIV-1 Capsid Trafficking and Infection in a Cyclophilin A-Dependent Manner","volume":"12","author":"Zhong","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.drudis.2022.05.016_b0350","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1073\/pnas.0402361101","article-title":"Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha","volume":"101","author":"Hatziioannou","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.05.016_b0355","doi-asserted-by":"crossref","first-page":"37025","DOI":"10.1074\/jbc.M606066200","article-title":"Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry","volume":"281","author":"Chatterji","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0360","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1742-4690-2-40","article-title":"TRIM5alpha selectively binds a restriction-sensitive retroviral capsid","volume":"2","author":"Sebastian","year":"2005","journal-title":"Retrovirology"},{"key":"10.1016\/j.drudis.2022.05.016_b0365","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41564-019-0592-5","article-title":"Cyclophilin A protects HIV-1 from restriction by human TRIM5\u03b1","volume":"4","author":"Kim","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.drudis.2022.05.016_b0370","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2020.08.039","article-title":"Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B","volume":"74","author":"Pfefferkorn","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2022.05.016_b0375","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jmv.20945","article-title":"Proteomic analysis of hepatitis B surface antigen positive transgenic mouse liver and decrease of cyclophilin A","volume":"79","author":"Zhao","year":"2007","journal-title":"J Med Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217433","article-title":"The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice","volume":"14","author":"Gallay","year":"2019","journal-title":"PLoS ONE"},{"issue":"403\u201314","key":"10.1016\/j.drudis.2022.05.016_b0385","article-title":"Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production","volume":"148","author":"Phillips","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2022.05.016_b0390","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2022.05.016_b0395","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2022.05.016_b0400","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","article-title":"Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity","volume":"66","author":"Shimura","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2022.05.016_b0405","article-title":"Cyclophilin A restricts influenza A virus replication through degradation of the M1 protein","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.05.016_b0410","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.24425","article-title":"Cyclophilin A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responses","volume":"6","author":"Liu","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2022.05.016_b0415","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1172\/JCI44947","article-title":"Virulence determinants of pandemic influenza viruses","volume":"121","author":"Tscherne","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2022.05.016_b0420","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.coi.2011.07.016","article-title":"The pathogenesis of influenza virus infections: the contributions of virus and host factors","volume":"23","author":"Fukuyama","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.drudis.2022.05.016_b0425","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1006\/viro.1993.1435","article-title":"Role of the M2 protein in influenza virus membrane fusion: effects of amantadine and monensin on fusion kinetics","volume":"195","author":"Bron","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2022.05.016_b0430","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0092-8674(85)90157-6","article-title":"Fusion mutants of the influenza virus hemagglutinin glycoprotein","volume":"40","author":"Daniels","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2022.05.016_b0435","doi-asserted-by":"crossref","first-page":"20067","DOI":"10.1074\/jbc.M114.569178","article-title":"The nuclear export protein of H5N1 influenza A viruses recruits Matrix 1 (M1) protein to the viral ribonucleoprotein to mediate nuclear export","volume":"289","author":"Brunotte","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0440","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1128\/JVI.74.4.1781-1786.2000","article-title":"Role of the influenza virus M1 protein in nuclear export of viral ribonucleoproteins","volume":"74","author":"Bui","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0445","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1128\/JVI.06586-11","article-title":"A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication","volume":"86","author":"Cao","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0450","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1128\/JVI.03024-12","article-title":"Tyrosine 132 phosphorylation of influenza A virus M1 protein is crucial for virus replication by controlling the nuclear import of M1","volume":"87","author":"Wang","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0455","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1128\/jvi.69.3.1964-1970.1995","article-title":"Nucleus-targeting domain of the matrix protein (M1) of influenza virus","volume":"69","author":"Ye","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000085","article-title":"Cellular proteins in influenza virus particles","volume":"4","author":"Shaw","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2022.05.016_b0465","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12250-018-0058-6","article-title":"CypA Regulates AIP4-Mediated M1 Ubiquitination of Influenza A Virus","volume":"33","author":"Mahesutihan","year":"2018","journal-title":"Virol Sin"},{"key":"10.1016\/j.drudis.2022.05.016_b0470","doi-asserted-by":"crossref","first-page":"28978","DOI":"10.1038\/srep28978","article-title":"Cyclophilin A protects mice against infection by influenza A virus","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.05.016_b0475","article-title":"Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.05.016_b0480","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9081599","article-title":"Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections","volume":"9","author":"Santos-Ferreira","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.drudis.2022.05.016_b0485","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbrc.2012.05.050","article-title":"Cyclophilin A inhibits rotavirus replication by facilitating host IFN-I production","volume":"422","author":"He","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2022.05.016_b0490","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.antiviral.2016.07.017","article-title":"Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development","volume":"133","author":"Yin","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.05.016_b0495","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/pmic.201100579","article-title":"Proteomic methods reveal cyclophilin A function as a host restriction factor against rotavirus infection","volume":"13","author":"He","year":"2013","journal-title":"Proteomics"},{"key":"10.1016\/j.drudis.2022.05.016_b0500","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2001.09702","article-title":"The controversial early history of cyclosporin","volume":"131","author":"Heusler","year":"2001","journal-title":"Swiss medical weekly"},{"key":"10.1016\/j.drudis.2022.05.016_b0505","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1021\/ja021327y","article-title":"Sanglifehrin\u2212Cyclophilin Interaction: Degradation Work, Synthetic Macrocyclic Analogues, X-ray Crystal Structure, and Binding Data","volume":"125","author":"Sedrani","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2022.05.016_b0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000439","article-title":"Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases","volume":"8","author":"Davis","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.drudis.2022.05.016_b0515","doi-asserted-by":"crossref","first-page":"12037","DOI":"10.1073\/pnas.192206699","article-title":"Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes","volume":"99","author":"Huai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.05.016_b0520","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0014-5793(94)80149-5","article-title":"The 3D structure of a cyclosporin analogue in water is nearly identical to the cyclophilin-bound cyclosporin conformation","volume":"340","author":"Wenger","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.drudis.2022.05.016_b0525","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0079-6107(97)00014-X","article-title":"Structures of cyclophilin-ligand complexes","volume":"67","author":"Taylor","year":"1997","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.drudis.2022.05.016_b0530","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.3390\/molecules18033502","article-title":"Technologies for the synthesis of mRNA-encoding libraries and discovery of bioactive natural product-inspired non-traditional macrocyclic peptides","volume":"18","author":"Ito","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.05.016_b0535","doi-asserted-by":"crossref","first-page":"13522","DOI":"10.1073\/pnas.212504399","article-title":"Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin","volume":"99","author":"Jin","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.drudis.2022.05.016_b0540","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1124\/dmd.110.032268","article-title":"Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin","volume":"38","author":"Amundsen","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.drudis.2022.05.016_b0545","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2011.11.032","article-title":"Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes","volume":"416","author":"Ogimura","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2022.05.016_b0550","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.trsl.2013.08.003","article-title":"Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4","volume":"162","author":"El-Sheikh","year":"2013","journal-title":"Transl Res"},{"key":"10.1016\/j.drudis.2022.05.016_b0555","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/eji.1830170921","article-title":"Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity","volume":"17","author":"Quesniaux","year":"1987","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.drudis.2022.05.016_b0560","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.173.3.619","article-title":"Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?","volume":"173","author":"Sigal","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2022.05.016_b0565","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0960-894X(01)80127-X","article-title":"Calcineurin has a very tight-binding pocket for the side chain of residue 4 of cyclosporin","volume":"4","author":"Papageorgiou","year":"1994","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.05.016_b0570","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1128\/jvi.69.2.814-824.1995","article-title":"Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication","volume":"69","author":"Steinkasserer","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.05.016_b0575","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.1021\/jm4007577","article-title":"Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147","volume":"56","author":"Malesevic","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0580","doi-asserted-by":"crossref","unstructured":"Lin K. Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 2011. p. 317\u201328.","DOI":"10.1002\/9780470929353.ch22"},{"key":"10.1016\/j.drudis.2022.05.016_b0585","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811","volume":"343","author":"Goto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2022.05.016_b0590","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1128\/AAC.01236-09","article-title":"Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors","volume":"54","author":"Puyang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.05.016_b0595","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","article-title":"The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro","volume":"43","author":"Paeshuyse","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2022.05.016_b0600","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"Coelmont","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.05.016_b0605","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/13543784.2012.658641","article-title":"Update on alisporivir in treatment of viral hepatitis C","volume":"21","author":"Flisiak","year":"2012","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.drudis.2022.05.016_b0610","doi-asserted-by":"crossref","first-page":"40293","DOI":"10.1074\/jbc.M506314200","article-title":"Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells","volume":"280","author":"Chatterji","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0615","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1016\/j.bmcl.2003.09.042","article-title":"Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs","volume":"13","author":"Evers","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.05.016_b0620","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.05.016_b0625","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(10)60678-2","article-title":"676 IN VITRO MODELS FOR ASSESSING THE RELATIVE RISK OF HYPERBILIRUBINEMIA ASSOCIATED WITH CYCLOPHILIN INHIBITOR THERAPY","volume":"52","author":"Wring","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2022.05.016_b0630","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1021\/jm500862r","article-title":"Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition","volume":"57","author":"Fu","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0635","doi-asserted-by":"crossref","first-page":"S493","DOI":"10.1016\/S0168-8278(13)61214-3","article-title":"1213 Cyclophilin inhibitor EDP-546 is a potential cornerstone drug for use in combination with ns5a and protease inhibitors due to its high barrier to hcv resistance","volume":"58","author":"Owens","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2022.05.016_b0640","unstructured":"Carling WR. Cyclosporin Analogs; 2011 [Vol. WO\/2012\/051193]."},{"key":"10.1016\/j.drudis.2022.05.016_b0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152036","article-title":"Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175","volume":"11","author":"Gallay","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.05.016_b0650","unstructured":"Hegmans AF, BW, Trepanier DJ, Abel MD, Sugiyama S, Ure DR. Cyclosporine Analogue Molecules Modified at Amino Acid 1 and 3; 2012."},{"key":"10.1016\/j.drudis.2022.05.016_b0655","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00253-021-11115-2","article-title":"Cyclophilin A: a key player for etiological agent infection","volume":"105","author":"Liao","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.drudis.2022.05.016_b0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134707","article-title":"The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action","volume":"10","author":"Gallay","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.05.016_b0665","first-page":"543","article-title":"Potent and Specific Inhibition of NTCP-Mediated HBV\/HDV Infection and Substrate Transporting by a Novel","volume":"64","author":"Liu","year":"2021","journal-title":"Oral-Available Cyclosporine A Analogue, J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0670","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0968-0896(96)00204-0","article-title":"Conformational control of cyclosporin through substitution of the N-5 position","volume":"5","author":"Papageorgiou","year":"1997","journal-title":"A new class of cyclosporin antagonists, Bioorganic & medicinal chemistry"},{"key":"10.1016\/j.drudis.2022.05.016_b0675","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1016\/j.bmcl.2010.09.036","article-title":"Synthesis and biological evaluation of [d-lysine]8cyclosporin A analogs as potential anti-HCV agents","volume":"20","author":"Scribner","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.05.016_b0680","doi-asserted-by":"crossref","first-page":"21965","DOI":"10.1074\/jbc.M501623200","article-title":"Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution","volume":"280","author":"Kallen","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0685","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1021\/acs.jmedchem.6b01329","article-title":"Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A","volume":"60","author":"Steadman","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0690","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2014.10.023","article-title":"Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection","volume":"22","author":"Hansson","year":"2015","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2022.05.016_b0695","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.1021\/acs.jmedchem.8b00802","article-title":"Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle","volume":"61","author":"Mackman","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0700","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1016\/j.bmcl.2016.09.039","article-title":"Design and synthesis of peptide-based macrocyclic cyclophilin inhibitors","volume":"26","author":"Granger","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.05.016_b0705","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1021\/acs.jmedchem.5b01064","article-title":"Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections","volume":"58","author":"Yang","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115679","article-title":"SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection","volume":"28","author":"Li","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112031","article-title":"Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment","volume":"188","author":"Han","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0720","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.ejmech.2011.02.023","article-title":"Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro","volume":"46","author":"Pang","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0725","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1016\/j.bmc.2006.04.026","article-title":"One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation","volume":"14","author":"Li","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0730","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1021\/jm050716a","article-title":"Structure-Based Design, Synthesis, and Biological Evaluation of Novel Inhibitors of Human Cyclophilin A","volume":"49","author":"Guichou","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0735","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1021\/jm9008295","article-title":"Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach","volume":"52","author":"Ni","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0740","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.3390\/molecules200610342","article-title":"Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization","volume":"20","author":"Yan","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.05.016_b0745","doi-asserted-by":"crossref","first-page":"12777","DOI":"10.1038\/ncomms12777","article-title":"Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities","volume":"7","author":"Ahmed-Belkacem","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2022.05.016_b0750","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1039\/C8SC03831G","article-title":"A computationally designed binding mode flip leads to a novel class of potent tri-vector cyclophilin inhibitors","volume":"10","author":"De Simone","year":"2019","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2022.05.016_b0755","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1016\/j.bmc.2009.02.051","article-title":"Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid","volume":"17","author":"Li","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0760","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/ci1004114","article-title":"Computational insight into small molecule inhibition of cyclophilins","volume":"51","author":"Sambasivarao","year":"2011","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2022.05.016_b0765","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1021\/bi9007287","article-title":"Isoform-specific inhibition of cyclophilins","volume":"48","author":"Daum","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2022.05.016_b0770","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00894-012-1560-7","article-title":"Discovery of novel low-molecular-weight HIV-1 inhibitors interacting with cyclophilin A using in silico screening and biological evaluations","volume":"19","author":"Tian","year":"2013","journal-title":"J Mol Model"},{"key":"10.1016\/j.drudis.2022.05.016_b0775","first-page":"326","article-title":"Strategy for Discovering Chemical Inhibitors of Human Cyclophilin A: Focused Library Design","volume":"8","author":"Li","year":"2006","journal-title":"Virtual Screening, Chemical Synthesis and Bioassay, Journal of Combinatorial Chemistry"},{"key":"10.1016\/j.drudis.2022.05.016_b0780","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbrc.2007.09.079","article-title":"Structure-based discovery of a family of synthetic cyclophilin inhibitors showing a cyclosporin-A phenotype in Caenorhabditis elegans","volume":"363","author":"Yang","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2022.05.016_b0785","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2007.03.023","article-title":"Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity","volume":"565","author":"Chen","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2022.05.016_b0790","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1248\/cpb.54.372","article-title":"Synthesis and peptidyl-prolyl isomerase inhibitory activity of quinoxalines as ligands of cyclophilin A","volume":"54","author":"Wang","year":"2006","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.drudis.2022.05.016_b0795","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.bmc.2005.11.006","article-title":"Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay","volume":"14","author":"Li","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0800","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/1087057110382775","article-title":"Discovery of novel cyclophilin A ligands using an H\/D exchange- and mass spectrometry-based strategy","volume":"15","author":"Dearmond","year":"2010","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.drudis.2022.05.016_b0805","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1021\/jm020409u","article-title":"Synthesis and Biological Evaluation of Non-Peptidic Cyclophilin Ligands","volume":"46","author":"Wu","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.05.016_b0810","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cbic.201000413","article-title":"Design and synthesis of conformationally constrained cyclophilin inhibitors showing a cyclosporin-A phenotype in C. elegans","volume":"12","author":"Dunsmore","year":"2011","journal-title":"ChemBioChem"},{"key":"10.1016\/j.drudis.2022.05.016_b0815","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/lt.500040406","article-title":"Risk factors for recurrence of hepatitis C after liver transplantation","volume":"4","author":"Herrero","year":"1998","journal-title":"Liver Transpl Surg"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:59:57Z","timestamp":1761224397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622002070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":163,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1359644622002070"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.016","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}